The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects
Open accessAbstract
Background and purpose: Atypical cannabinoids are thought to cause vasodilatation through an as‐yet unidentified ‘CBx’ receptor. Recent reports suggest GPR55 is an atypical cannabinoid receptor, making it a candidate for the vasodilator ‘CBx’ receptor. The purpose of the present study was to test the hypothesis that human recombinant GPR55 is activated by atypical cannabinoids and mediates vasodilator responses to these agents. Experimental approach: Human recombinant GPR55 was expressed in HEK293T cells and specific GTP γ S activity was monitored as an index of receptor activation. In GPR55‐deficient and wild‐type littermate control mice, in vivo blood pressure measurement and isolated resistance artery myography were used to determine GPR55 dependence of atypical cannabinoid‐induced haemodynamic and vasodilator responses. Key results: Atypical cannabinoids O‐1602 and abnormal cannabidiol both stimulated GPR55‐dependent GTP γ S activity (EC 50 approximately 2 n M), whereas the CB 1 and CB 2‐selective agonist WIN 55,212‐2 showed no effect in GPR55‐expressing HEK293T cell membranes. Baseline mean arterial pressure and heart rate were not different between WT and GPR55 KO mice. The blood pressure‐lowering response to abnormal cannabidiol was not different between WT and KO mice (WT 20±2%, KO 26±5% change from baseline), nor was the vasodilator response to abnormal cannabidiol in isolated mesenteric arteries (IC 50 approximately 3 μ M for WT and KO). The abnormal cannabidiol vasodilator response was antagonized equivalently by O‐1918 in both strains. Conclusions: These results demonstrate that while GPR55 is activated by atypical cannabinoids, it does not appear to mediate the vasodilator effects of these agents. British Journal of Pharmacology (2007) 152, 825–831; doi:10.1038/sj.bjp.0707419; published online 20 August 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 2×
“, 2002), while CB2 is expressed peripherally in immune and haematopoietic cells (Munro et al., 1993).”
BackgroundVanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142 · cited 2×
“Endocannabinoids such as anandamide have been shown to stimulate other nonputative cannabinoid (non-CB1, CB2 or CBx) targets such as the transient receptor potential vallinoid type 1 (TRPV1) channel resulting in CGRP-dependent vasodilatation (Zygmunt et al., 1999).”
Background
Cited by
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomas
Stella, N. (2010) · Glia · doi:10.1002/glia.20983 · Cited by 527
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
“In addition, it has been found that GPR55 is activated by one CB1-selective antagonist (AM251) but not by another (AM281), and that it is not activated by the CB1/CB2 agonist R-(+)-WIN55212 (Johns et al., 2007; Ryberg et al., 2007; Lauckner et al., 2008).”
BackgroundBrown, A. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707481 · Cited by 409
Self-citationReceptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists
Pertwee, R. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790980050 · Cited by 335
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo
Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., Ross, R. A., & Rogers, M. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902743106 · Cited by 330
Signal transduction of the CB1 cannabinoid receptor
Turu, G., & Hunyady, L. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0190 · Cited by 325
Lipid G Protein-coupled Receptor Ligand Identification Using β-Arrestin PathHunter™ Assay
Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D. G., Caldwell, J. S., & Chen, Y. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806516200 · Cited by 311
The enigmatic pharmacology of GPR55
Ross, R. A. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.004 · Cited by 296
Henstridge, C. M., Balenga, N. A. B., Ford, L. A., Ross, R. A., Waldhoer, M., & Irving, A. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-108670 · Cited by 285
Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands
Kapur, A., Zhao, P., Sharir, H., Bai, Y., Caron, M. G., Barak, L. S., & Abood, M. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.050187 · Cited by 274
Endocannabinoid signaling in microglial cells
Stella, N. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.037 · Cited by 272
Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., et al. (2008) · Pain · doi:10.1016/j.pain.2008.04.006 · Cited by 270
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
Pacher, P., & Haskó, G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707582 · Cited by 217
Beyond THC and Endocannabinoids
Pacher, P., Kogan, N. M., & Mechoulam, R. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021441 · Cited by 175
Dunn, S. L., Wilkinson, J. M., Crawford, A., Bunning, R. A. D., & Le Maitre, C. L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0001 · Cited by 62
Metadata
- Authors
- Johns, D. G., Behm, D. J., Walker, D. J., Ao, Z., Shapland, E. M., Daniels, D. A., Riddick, M., Dowell, S., Staton, P. C., Green, P., Shabon, U., Bao, W., Aiyar, N., Yue, T., Brown, A. J., Morrison, A. D., & Douglas, S. A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 152
- Issue
- 5
- Pages
- 825-831
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1578252886
- Cited by
- 242
- References
- 2
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.